Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05684848
Other study ID # LFV_PRE
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2022
Est. completion date May 31, 2024

Study information

Verified date January 2023
Source Noos S.r.l.
Contact Michele Miraglia del Giudice, Prof
Phone 0815665470
Email Michele.MIRAGLIADELGIUDICE@unina2.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine whether or not preventive administration of resveratrol in the form of a nasal spray is effective in reducing the number of asthma exacerbations typical of preschool wheezing children who develop viral infections.


Description:

The surface of the mucous membranes represents the first gateway for many viral agents including respiratory and intestinal ones which have the greatest epidemiological value. Viruses cause damage to these epithelia and can favor bacterial superinfection as well as complications of already existing pathologies; it is therefore essential to identify non-toxic substances that can hinder the entry of the virus and consequently its replication. Both wheezing and viral infections are common in children, especially under the age of five. In fact, it is recorded that around 25% of children within nine months of age and 50% of children within six years of age have at least one episode of wheezing. Wheezing in young children can have a different etiology: it can be due to an underlying disease such as airway malformation, internal or external airway narrowing, and cystic fibrosis, or it can occur without an underlying disease. In the latter case, the viral infection represents one of the main causes of wheezing especially in children under five/six years of age. However, not all viral infections cause wheezing.Numerous studies have confirmed a correlation between viral infections and asthma exacerbations in both adults and children. Furthermore, new evidence suggests that viral respiratory infections in the early years of life are related to the medium- and long-term development of asthma There is ample clinical evidence demonstrating a link between early viral infections (especially RV and RSV) and the onset of asthma exacerbations. In addition to the viruses mentioned above, enteroviruses, bocaviruses, parainfluenza viruses, coronaviruses, metapneumoviruses, influenza viruses and adenoviruses also seem to be implicated. RSV (respiratory syncytial virus) is the most common cause of bronchiolitis in the first year of life, causes hospitalization and typically circulates in temperate climates from November to April with peaks in the winter months Although RSV has long been identified as the leading cause of childhood bronchiolitis, the use of molecular techniques, such as PCR, has also identified rhinovirus as a causative agent of asthma exacerbations. Rhinovirus, which circulates year-round with peaks during the fall and spring, as well as being a cause of upper respiratory tract infections, has been shown in some clinical investigations to infect the lower airways, to be associated with childhood bronchiolitis and become a dominant pathogen in wheezing disease as children get older. In the search for new therapeutic and prevention alternatives that can be considered a valid contribution to reduce the effects of viral infection, the focus has been on effective and early treatments to help prevent the spread of the virus or to neutralize viruses at an early stage when they are lodged in the upper respiratory tract and therefore in the nose, since this is the probable and first route of entry for viruses and therefore for infections. A nasal spray based on resveratol and carboxymethylbetaglucan (Linfovir® plus nasal spray) was therefore considered, which could be useful in hindering the entry of pathogens (viruses and bacteria) into the nasal cavities thanks to the mechanical action of the washing which goes to counter the engraftment and the consequent easier proliferation of the virus. Furthermore, the product contains resveratrol, a substance of natural origin, produced by various plants in response to stress or injury induced by microorganisms or environmental hazards which protects fruit and vegetables from fungal infections. This plant extract has been widely recognized as having antioxidant properties capable of counteracting the inflammatory stages associated with pathologies of the rhinosinusal tract. Patients infected with respiratory viruses, in fact, show an increased inflammatory state, with high levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)α, interleukin IL-6, IL-8 and interferons, in the nasopharyngeal fluids and in plasma. Additionally, in severe viral infections, reactive oxygen species (ROS) produced by inflammatory cells, such as polymorphonuclear cells and neutrophils, recruited to the site of inflammation lead to lung damage. On the basis of these assumptions, an interventional, randomized, multicenter and controlled clinical study was designed to evaluate whether the spray solution, used to hydrate and clean the nasal mucous membranes at a dosage of 2 sprays per nostril, 2 times a day (in prevention) and 2 sprays per nostril, 4 times a day (in the acute phase), is safe and effective in preventing and treating viral infections typical of the autumn/winter season in preschool wheezing children particularly prone to infections and asthma exacerbations. Thanks to the mechanical effect of washing and through the antioxidant and anti-inflammatory efficacy of resveratrol, amply demonstrated in vitro, the Investigators will evaluate, in the present study, whether the topical administration of resveratrol at the level of the nasal district, in the form of a nasal spray, is able to reduce the number of days in which preschool children present symptoms attributable to respiratory infections.


Recruitment information / eligibility

Status Recruiting
Enrollment 252
Est. completion date May 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 6 Years
Eligibility Inclusion Criteria: - Children diagnosed with wheezing - Patients aged between 3 and 6 years (inclusive) at the time of enrollment of both genders - Signature of the informed consent - Availability of a mobile phone capable of installing VIR@PP Exclusion Criteria: - Inability to adequately understand the Italian language - Presence of autoimmune pathologies, immunodeficiency, neuromuscular diseases, congenital cardiomyopathies, metabolic diseases - Presence of other syndromes and genetic pathologies - Patients on therapy with other drugs (steroids for topical and/or oral use) - Abnormalities of the nose or other conditions (e.g. severe hypotonia etc…) which make the administration of a nasal spray impossible or unsafe - Denial of informed consent - Participation in other clinical studies

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Resveratrol + CMG
As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
Isotonic solution
As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.

Locations

Country Name City State
Italy University of Campania Luigi Vanvitelli Naples

Sponsors (1)

Lead Sponsor Collaborator
Noos S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the number of days with respiratory symptoms compared to placebo To determine whether taking resveratrol in the form of a nasal spray changes the number of days with respiratory symptoms compared to placebo. 3 months
Secondary In case of exacerbations, verify the change in the number of respiratory exacerbations and their duration of the group treated with resveratrol in the form of nasal spray vs the control group. In case of exacerbations, verify the change in the number of respiratory exacerbations and their duration of the group treated with resveratrol in the form of nasal spray vs the control group. The number of days of use of antipyretics, oral corticosteroids and salbutamol will also be evaluated in the two groups. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04669288 - AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Phase 3
Withdrawn NCT04584034 - Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial Phase 4
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Enrolling by invitation NCT00775697 - Montelukast in Children With Wheezing Phase 4
Completed NCT00749528 - Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing N/A
Recruiting NCT00494624 - Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Phase 4
Recruiting NCT04128592 - Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers N/A
Recruiting NCT06093152 - Video Assisted Study of Salbutamol Response in Viral Wheezing
Completed NCT01452945 - Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing N/A
Withdrawn NCT00628303 - A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants Phase 3
Completed NCT01028560 - Allergy Immunotherapy for the Reduction of Asthma Phase 1/Phase 2
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00507676 - Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing N/A
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Recruiting NCT06106646 - Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
Recruiting NCT05710081 - Bacterial Lysate In Preventing Asthma Phase 3
Completed NCT04011709 - A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy Early Phase 1
Active, not recruiting NCT03377192 - Impedance Pneumography in Assessment of Asthma Control in Preschool Children
Completed NCT01142505 - Wheeze and Intermittent Treatment Phase 3
Active, not recruiting NCT04942483 - Using Specific Tests in Preschool Children With Wheeze to Help us Determine the Necessity of Inhaled Corticosteroid Therapy (Feasibility Study).